Early-stage studies of medications to treat high-risk alcohol use may be missing opportunities to identify potential therapeutic effects in certain populations, including women and people at risk for relapse, according to a systematic review published in Alcohol: Clinical & Experimental Research.
This article was originally published on MedicalXpress.com

